Affordable Access

deepdyve-link
Publisher Website

Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016.

Authors
  • Martínez-Gómez, Xavier1
  • Curran, Adrian2
  • Campins, Magda1
  • Alemany, Laia3
  • Rodrigo-Pendás, José Ángel1
  • Borruel, Natalia4
  • Castellsagué, Xavier3
  • Díaz-de-Heredia, Cristina5
  • Moraga-Llop, Fernando A6
  • Del Pino, Marta7, 8
  • Torné, Aureli7, 8
  • 1 Servei de Medicina Preventiva i Epidemiologia, Hospital Universitari Vall d'Hebron - Universitat Autònoma de Barcelona, Barcelona, España.
  • 2 Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron - Universitat Autònoma de Barcelona, Barcelona, España.
  • 3 Programa de Recerca en Epidemiologia del Càncer, Institut Català d'Oncologia - IDIBELL CIBER Epidemiología y Salud Pública, Barcelona, España.
  • 4 Unitat d'Atenció Crohn-Colitis, Servei d'Aparell Digestiu; Hospital Universitari Vall d'Hebron - Universitat Autònoma de Barcelona, Barcelona, España.
  • 5 Servei d'Oncologia i Hematologia Pediàtrica, Hospital Universitari Vall d'Hebron - Universitat Autònoma de Barcelona, Barcelona, España.
  • 6 Asociación Española de Vacunología, Barcelona, España.
  • 7 Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Facultad de Medicina, Universidad de Barcelona, Barcelona, España.
  • 8 Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic de Barcelona, Barcelona, España.
Type
Published Article
Journal
Eurosurveillance
Publisher
European Centre for Disease Control and Prevention (ECDC)
Publication Date
Feb 01, 2019
Volume
24
Issue
7
Identifiers
DOI: 10.2807/1560-7917.ES.2019.24.7.1700857
PMID: 30782268
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9-26 years; men who have sex with men aged 9-26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9-26 years; and patients diagnosed with recurrent respiratory papillomatosis. Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence-based guidelines on HPV vaccination in high-risk populations in Spain, based on best available scientific evidence.

Report this publication

Statistics

Seen <100 times